检索结果-南通市图书馆

Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis c patients

World Journal of clinical cases 2022年第17期10卷 5566-5576页

作者： Anya Mezina Arunkumar Krishnan Tinsay A Woreta Kevin B Rubenstein Eric Watson Po-Hung chen carla Rodriguez-Watson Department of Medicine Johns Hopkins School of MedicineBaltimoreMD 21287United States Division of Gastroenterology and Hepatology Johns Hopkins School of MedicineBaltimoreMD 21231United States Mid-Atlantic Permanente Research Institute Kaiser Permanente Mid-Atlantic StatesRockville 20852United States Department of Health Policy and Management Bloomberg School of Public HealthJohns Hopkins UniversityBaltimoreMD 21287United States Innovation in Medical Evidence Development and Surveillance(IMEDS)Program Reagan-Udall Foundation for the FDAWashington20036United States

BAcKGROUND Liver fibrosis is a common pathway of liver injury and is a feature of most chronic liver *** progression varies markedly in patients with hepatitis c virus(HcV).Liver stiffness has been recommended as a parameter of fibrosis progression/regression in patients with *** To investigate changes in liver stiffness measured by transient elastography(TE)in a large,racially diverse cohort of United States patients with chronic hepatitis c(cHc).METHODS We evaluated the differences in liver stiffness between patients treated with direct-acting antiviral(DAA)therapy and untreated *** had≥2 TE measurements and no prior DAA *** used linear regression to measure the change in liver stiffness between first and last TE in response to treatment,controlling for age,sex,race,diabetes,smoking status,human immunodeficiency virus status,baseline alanine aminotransferase,and baseline liver *** regression models analyzed the change in liver stiffness as measured by kPa,stratified by cirrhosis *** Of 813 patients,419(52%)initiated DAA *** liver stiffness was 12 kPa in 127(16%).Median time between first and last TE was 11.7 and 12.7 mo among treated and untreated patients,*** was no significant change in liver stiffness observed over time in either the group initiating DAA treatment(0.016 kPa/month;cI:-0.051,0.084)or in the untreated group(0.001 kPa/mo;cI:-0.090,0.092),controlling for covariates.A higher baseline kPa score was independently associated with decreased liver *** DAA treatment was not associated with a differential change in liver stiffness over time in patients with cHc compared to untreated patients.

关键词： chronic hepatitis c Liver stiffness cirrhosis Transient elastography Direct-acting antiviral therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis c

引用

World Journal of Gastroenterology 2023年第6期29卷 949-966页

作者： MichałBrzdęk Dorota Zarębska-Michaluk Federica Invernizzi Marta cilla Krystyna Dobrowolska Robert Flisiak collegium Medicum Jan Kochanowski UniversityKielce 25-516Poland of Infectious Diseases Jan Kochanowski UniversityKielce 25-516Poland center for Liver Disease Division of Internal Medicine and HepatologyIRCCS Ospedale San RaffaeleMilan 20-132Italy Department of Infectious Diseases and Hepatology Medical University of BiałystokBiałystok 15-540Poland

chronic infection with the hepatitis c virus(HcV)remains a major health problem affecting approximately 58 million people *** the era of interferon(IFN)-based regimens,patients particularly infected with genotypes 1 and 4 achieved a low response *** implementation of direct-acting antivirals changed the landscape of HcV *** increase in effectiveness provided us with the hope of eliminating HcV as a significant public threat by *** the following years,there was an observed improvement in the treatment of HcV with genotype-specific regimens and highly effective pangenotypic options that are the most recent stage of the *** optimization of therapy was accompanied by changes in the patient profile from the beginning of the IFN-free era over *** treated with antiviral therapies were younger in successive periods,less burdened with comorbidities and comedications,more frequently treatment-naïve and had less advanced liver *** the IFN-free era,specific subpopulations such as patients with HcV/HIV coinfection,those with a history of previous treatment,patients with renal impairment or with cirrhosis had lower chances for a virologic ***,these populations should no longer be considered difficult to *** the high effectiveness of HcV therapy,there is a small percentage of patients with treatment ***,they can be effectively retreated with pangenotypic rescue regimens.

关键词： hepatitis c virus Interferon Direct-acting antiviral Epidemiology chronic hepatitis c

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Acute-on-chronic liver failure induced by antiviral therapy for chronic hepatitis c: A case report

引用

World Journal of clinical cases 2023年第30期11卷 7463-7468页

作者： Jiang-Li Zhong Ling-Wei Zhao Ying-Hua chen Ya-Wen Luo Department of Infectious Diseases The Affiliated Hospital of Zunyi Medical UniversityZunyi 563000Guizhou ProvinceChina Department of Hematology The Affiliated Hospital of Zunyi Medical UniversityZunyi 563000Guizhou ProvinceChina

BAcKGROUND There have been no reports of acute-on-chronic liver failure(AcLF)during treatment of chronic hepatitis c(cHc)with direct-acting antivirals(DAAs).cASE SUMMARY We report a 50-year-old male patient with *** patient sought medical attention from the Department of Infectious Diseases at our hospital due to severe yellowing of the skin and sclera,which developed 3 mo previously and attended two consecutive hospitals without finding the cause of liver *** was not until 1 mo ago that he was diagnosed with cHc at our *** discharge,he was treated with *** treatment,AcLF occurred,and timely measures such as liver protection,enzyme lowering,anti-infective treatment,and suppression of inflammatory storms were implemented to control the *** DAA drugs significantly improve the cure rate of ***,when patients have factors such as autoimmune attack,coinfection,or unclear hepatitis c virus genotype,close monitoring is required during DAA treatment.

关键词： chronic hepatitis c Acute-on-chronic liver failure Direct acting antivirals Sofosbuvir-velpatasvir case report

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Direct-acting antivirals for chronic hepatitis c treatment: The experience of two tertiary university centers in Brazil

引用

World Journal of Hepatology 2022年第1期14卷 195-208页

作者： Mariana Sandoval Lourenço Patricia Momoyo Y Zitelli Marlone cunha-Silva Arthur Ivan N Oliveira cláudia P Oliveira Tiago Sevá-Pereira Flair Josécarrilho Mario G Pessoa Daniel F Mazo Division of Gastroenterology Department of Internal MedicineSchool of Medical SciencesUniversity of CampinasSao Paulo 13083-878Brazil Division of clinical Gastroenterology and Hepatology Department of GastroenterologyUniversity of São Paulo School of MedicineSao Paulo 05403-900Brazil

BAcKGROUND hepatitis c virus(HcV)treatment has undergone major changes in recent *** interferon-based therapies have been replaced by oral direct-acting antivirals(DAA)regimens,with high sustained virologic response(SVR)rates,and a lower incidence of adverse events(AEs).AIM To evaluate the efficacy and safety of DAAs for HcV treatment in subjects from two tertiary university centers in *** This is a multicenter retrospective cohort study of 532 patients with chronic hepatitis c(cHc),undergoing treatment with interferon-free regimens from November 2015 to November *** therapeutic regimen was defined by the current Brazilian guidelines for HcV management at the time of ***,anthropometric,clinical,and laboratory variables were *** were assessed at 12 to 24 wk after therapy by intention-to-treat(ITT),and modified ITT(m-ITT)*** and serious adverse events(SAEs)were *** the statistical analysis,a P value ofconsidered *** The mean age was 56.88 years,with 415(78.5%)being HcV genotype 1,followed by genotype 3(20.1%).Moreover,306(57.5%)subjects had cirrhosis,and a third of them had decompensated ***(SOF)plus daclatasvir±ribavirin was the most frequently used treatment(66.9%),followed by SOF plus simeprevir(21.2%).The overall ITT SVR was 92.6%(493/532),while the m-ITT SVR was 96.8%(493/509).Variables associated with treatment failure via ITT evaluation were hepatic encephalopathy(OR:4.320;95%cI:1.920-9.721,P=0.0004),presence of esophageal varices(OR:2.381;95%cI:1.137-4.988,P=0.0215),previous portal hypertensive bleeding(OR:2.756;95%cI:1.173-6.471,P=0.02),higher model for end-stage liver disease scores(OR:1.143,95%cI:1.060–1.233,P=0.0005),lower serum albumin levels(OR:0.528,95%cI:0.322-0.867,P=0.0115),higher serum creatinine(OR:1.117,95%cI:1.056-1.312,P=0.0033),and international normalized ratio(INR)levels(OR:5.542,95%cI:2.023-15.182,P=0.0009).AEs were reported

关键词： chronic hepatitis c Antiviral agents hepatitis c virus Sustained virologic response Liver cirrhosis Safety

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Metabolomics in chronic hepatitis c:Decoding fibrosis grading and underlying pathways

引用

World Journal of Hepatology 2023年第11期15卷 1237-1249页

作者： Adriana camargo Ferrasi Samara Vitória Granja Lima Aline Faria Galvani Jeany Delafiori Flavia Luísa Dias-Audibert Rodrigo Ramos catharino Giovanni Faria Silva Roberta Rodrigues Praxedes Driele Bretones Santos Dayane Trevisan de Macedo Almeida Estela Oliveira Lima Department of Internal Medicine Sao Paulo State UniversityBotucatu 18618-686Brazil Innovare Biomarkers Laboratory University of CampinasCampinas 13083-877Brazil

BAcKGROUND chronic hepatitis c(cHc)affects 71 million people globally and leads to liver issues such as fibrosis,cirrhosis,cancer,and death.A better understanding and prognosis of liver involvement are vital to reduce morbidity and *** accurate identification of the fibrosis stage is crucial for making treatment decisions and predicting *** used to grade fibrosis include histological analysis and imaging but have *** markers such as molecular biomarkers can offer valuable insights into *** To identify potential biomarkers that might stratify these lesions and add information about the molecular mechanisms involved in the *** Plasma samples were collected from 46 patients with hepatitis c and classified into fibrosis grades F1(n=13),F2(n=12),F3(n=6),and F4(n=15).To ensure that the identified biomarkers were exclusive to liver lesions(cHc fibrosis),healthy volunteer participants(n=50)were also *** untargeted metabolomic technique was used to analyze the plasma metabolites using mass spectrometry and database *** analyses were performed to identify differential biomarkers among *** Six differential metabolites were identified in each grade of *** six-metabolite profile was able to establish a clustering tendency in patients with the same grade of fibrosis;thus,they showed greater efficiency in discriminating *** This study suggests that some of the observed biomarkers,once validated,have the potential to be applied as prognostic ***,it suggests that liquid biopsy analyses of plasma metabolites are a good source of molecular biomarkers capable of stratifying patients with cHc according to fibrosis grade.

关键词： chronic hepatitis c Fibrosis Metabolome Biomarkers Plasma Liquid biopsy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis c

引用

World Journal of Gastroenterology 2010年第35期16卷 4394-4399页

作者： Fan-Pu Ji Zheng-Xiao Li Hong Deng Hong-An Xue Yuan Liu Min Li Department of Dermatology Second Affiliated Hospital china Yuan Liu Department of Dermatology Second Afliated HospitalCollege of MedicineXi’an Jiaotong UniversityXi’an 710004Shaanxi ProvinceChina Department of Pulmonary Medicine Second Afliated HospitalCollege of MedicineXi’an Jiaotong University Xi’an 710004Shaanxi ProvinceChina Department of Imageology First Affiliated HospitalCollege of MedicineXi’an Jiaotong UniversityXi’an 710061Shaanxi ProvinceChina

Interstitial pneumonitis(IP) is an uncommon pulmonary complication associated with interferon(IFN) therapy for chronic hepatitis c virus(HcV) *** can occur at any stage of HcV treatment,ranging from 2 to 48 wk,usually in the first 12 *** most common symptoms are dyspnoea,dry cough,fever,fatigue,arthralgia or myalgia,and anorexia,which are reversible in most cases after cessation of IFN therapy with a mean subsequent recovery time of 7.5 *** lavage in combination with chest high resolution computed tomography has a high diagnostic *** discontinuation of medication is the cornerstone,and corticosteroid therapy may not be essential for patients with mild-moderate pulmonary functional *** severity of pulmonary injury is associated with the rapid development of *** suggest that methylprednisolone pulse therapy followed by low dose prednisolone for a short term is necessary to minimize the risk of fatal pulmonary damage if signs of significant pulmonary toxicity occur in earlier *** should be aware of the potential pulmonary complication related to the drug,so that an early and opportune diagnosis can be made.

关键词： chronic hepatitis c Interferon α Interstitial pneumonitis Management corticosteroid therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Peginterferon alfa-2a for the treatment of chronic hepatitis c in the era of direct-acting antivirals

引用

Hepatobiliary & Pancreatic Diseases International 2017年第5期16卷 470-479页

作者： Yan Huang Ming-Hui Li Min Hou Yao Xie Shanghai Roche Pharmaceuticals Ltd. Shanghai 201203 China Liver Disease center Beijing Ditan Hospital Capital Medical University Beijing 100015 China

BAcKGROUND: The availability of novel direct-acting antivirals (DAAs) represents a new era of curative hepatitis c virus (HcV) treatment, with over 95% of patients infected with HcV genotype 1 achieving sustained virological response (SVR). Nevertheless, the majority of patients globally are unable to access these treatments because of cost and infrastructure constraints and, thus, remain untreated and uncured. DATA SOURcE: Relevant articles of peginterferon (PegIFN)-based treatments in HcV and sofosbuvir-based treatments, simeprevir, daclatasvir/asunaprevir, ritonavir-boosted paritaprevir/ombitasvir/dasabuvir, and grazoprevir/elbasvir, were searched in PubMed database, including general population and special population. RESULTS: PegIFN in combination with ribavirin remains an important and relevant option for some patients, achieving SVR rates of up to 79% in genotype 1 and 89% in genotype 2 or 3 infections, which increases for patients with favorable IL28B genotypes. Triple therapy of DAA plus PegIFN/ribavirin is effective in treating difficult-to-cure patients infected with HcV genotype 3 or with resistance-associated variants. Owing to its long history in HcV management, the efficacy, tolerability and long-term outcomes associated with PegIFN alfa-2a are well established and have been validated in large-scale studies and in clinical practice for many populations. Furthermore, emerging data show that IFN-induced SVR is associated with lower incidences of hepatocellular carcinoma compared with DAAs. On the contrary, novel DAAs have yet to be studied in special populations, and long-term outcomes, particularly tumor development and recurrence in patients with cirrhosis and/or hepatocellular carcinoma, and reactivation of HBV in dually infected patients, are still unclear. cONcLUSION: In this interferon-free era, PegIFN-based regimens remain a safe and effective option for selected HcV patients.

关键词： chronic hepatitis c direct-acting antivirals hepatitis c virus peginterferon alfa-2a ribavirin

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis c

引用

World Journal of Gastroenterology 2010年第21期16卷 2638-2647页

作者： Eduardo Vilar Gomez Yadina Martinez Perez Hector Vega Sanchez Gretel Riveron Forment Enrique Arus Soler Luis calzadilla Bertot Ali Yasells Garcia Maria del Rosario Abreu Vazquez Licet Gonzalez Fabian Department of Hepatology National Institute of GastroenterologyHavana 10400Cuba Department of Gastroenterology National Institute of GastroenterologyHavana 10400Cuba Department of Immunology National Institute of GastroenterologyHavana 10400Cuba Department of Oxidative Stress National Genetic CenterHavana 10400Cuba Department of Biostatistics National Institute of GastroenterologyHavana 10400Cuba Department of Pathology Institute of GastroenterologyHavana 10400Cuba

AIM:To investigate the efficacy of Viusid,a nutritional supplement,as an antioxidant and an immunomodulator in patients with chronic hepatitis ***:Sixty patients with chronic hepatitis c who were non-responders to standard antiviral treatment were randomly assigned to receive Viusid(3 sachets daily,n=30) or placebo(n=30) for 24 *** primary outcome was the change in serum malondialdehyde and 4-hydroxyalkenals(lipid peroxidation products).Secondary outcomes were changes in serum tumor necrosis factor-α(TNF-α),interferon-γ(IFN-γ) and interleukin-10(IL-10).RESULTS:Statistically significant reductions in serum 4-hydroxyalkenals and malondialdehyde levels were observed in both groups in comparison with pretreatment values,but the patients who received Viusid showed a more marked reduction as compared with the control group(P=0.001).TNF-α levels significantly increased from 6.9 to 16.2 pg/mL(Pceived placebo in comparison with almost unchanged levels,from 6.6 to 7.1 pg/mL(P=0.26),in the patients treated with Viusid(P=0.001).In addition,IL-10 levels were markedly increased in the patients treated with Viusid(from 2.6 to 8.3 pg/mL,P=0.04) in contrast to the patients assigned to placebo(from 2.8 to 4.1 pg/mL,P=0.09)(P=0.01).Likewise,the administration of Viusid markedly increased mean IFN-γ levels from 1.92 to 2.89 pg/mL(Pcomparison with a reduction in mean levels from 1.80 to 1.68 pg/mL(P=0.70) in the placebo group(Pcate that treatment with Viusid leads to a notable improvement of oxidative stress and immunological parameters in patients with chronic hepatitis c.

关键词： Antioxidant therapy chronic hepatitis c cytokines Immunomodulatory therapy Nutritional supplement Oxidative stress

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Immediate virological response predicts the success of shortterm peg-interferon monotherapy for chronic hepatitis c

引用

World Journal of Gastroenterology 2010年第12期16卷 1506-1511页

作者： Masayoshi Yada Akihide Masumoto Naoki Yamashita Kenta Motomura Toshimasa Koyanagi Shigeru Sakamoto Department of Hepatology Iizuka Hospital

AIM:To investigate the efficacy of short-term peginterferon(PEG-IFN)monotherapy for chronic hepatitis c patients who achieved an immediate virological ***:Defining an"immediate virological response(IVR)"as the loss of serum hepatitis c virus(HcV) RNA 7 d after the first administration of PEG-IFNα,we conducted a 12-wk course of PEG-IFNα2a monotherapy without the addition of ribavirin for 38 patients who had low pretreatment HcV RNA load and exhibited *** patients included 21 men and 17 women,whose ages ranged from 22 to 77 years(mean±SD:52.0±17.8 years).There were 4 patients with HcV genotype 1b,23 patients with genotype 2a and 4 patients with genotype *** genotype was not determined for the remaining 7 *** were categorized into a sustained virological response(SVR)group,if serum HcV RNA remained negative for 24 wk after the end of treatment,or into a relapse ***:Based on the intention-to-treat analysis,35 patients(92.1%)achieved *** patient(2.6%)relapsed with serum HcV RNA 12 wk after the end of *** patients(5.3%)withdrew from the study during the 24-wk follow-up *** regard to the HcV RNA genotype,the SVR rates were 100%(4/4) for genotype 1b,95.7%(22/23)for genotype 2a and 100%(4/4)for genotype *** SVR rate in 7 patients,whose HcV RNA genotypes were not determined,was 71.4%(5/7).cONcLUSION:Short-term PEG-IFNα2a monotherapy is highly effective for chronic hepatitis c patients who have low pretreatment HcV RNA load and exhibit IVR.

关键词： chronic hepatitis c Immediate virological response Interferon therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Alkaline phosphatase predicts relapse in chronic hepatitis c patients with end-of-treatment response

引用

World Journal of Gastroenterology 2010年第19期16卷 2407-2410页

作者： Gerd Bodlaj Rainer Hubmann Karim Saleh Tatjana Stojakovic Georg Biesenbach Jrg Berg Second Department of Medicine General Hospital Linz A-4020 Linz Austria clinical Institute of Medical and chemical Laboratory Diagnostics Medical University of Graz A-8010 Graz Austria Institute of Laboratory Medicine General Hospital Linz A-4020 Linz Austria

AIM: To investigate relapse predictors in chronic hepatitis c (cHc) patients with end-of-treatment response (ETR), after pegylated interferon-α (PegIFN-α) and ribavirin treatment. METHODS: In a retrospective study we evaluated a spectrum of predictors of relapse after PegIFN-α and ribavirin treatment in 86 cHc patients with ETR. Viral loads were determined with real-time reverse transcrip-tion polymerase chain reaction. hepatitis c virus geno-typing was performed by sequencing analysis. Patients with genotype 1 were treated for 48 wk with 180 μg PegIFN-α2a or 1.5 μg/kg PegIFN-α2b once weekly plus ribavirin at a dosage of 1000 mg/d for those under 75 kg or 1200 mg/d for those over 75 kg. Patients with geno- types 2 and 3 were treated for 24 wk with 180 μgPegIFN-α2a or 1.5 μg/kg PegIFN-α2b once weekly plus ribavirin at a dosage of 800 mg/d. RESULTS: In all ETR patients, binary logistic regression analysis identif ied absence of complete early virological response (cEVR) (OR 27.07, 95% cI: 3.09-237.26, P cI: 2.1-18.03, P 26 kg/m2 (OR: 8.27, 95% cI: 2.22-30.84, P ctors of relapse. When cEVR patients were analyzed exclusively, ALP prior to therapy ctor of relapse. cONcLUSION: Lower levels of ALP prior to, during and after therapy seem to be associated with a higher risk of relapse in cHc patients with ETR.

关键词： Alkaline phosphatase chronic hepatitis c Pegylated interferon Predictor Relapse

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：